CAL101
Asset
Blocks S100A4 to inhibit profibrotic signaling and tissue fibrosis.
- Stage
- Phase 2
- Modality
- Antibody
- Target
- S100A4
- 1
- Indication
- 0
- Trials
- 1
- Developer
Indications
1Idiopathic pulmonary fibrosis
Phase 2, businesswire.com, 13 Oct 2026
In the full profile
- Targets and what it contains1
- Owner and partners1
- Evidence for its targets1
- Competitors3
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.